Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced recipients of its eighth annual Communications Grant Program on February 9, 2026, awarding two grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) community.

The grants fund digital communications, bilingual video resources, a pediatric clinic toolkit, and a six-month Canadian awareness campaign to expand HCM education and community engagement.

Key Figures

Number of grants: 2 grants Program year: Eighth annual Video series length: 5-part video series +2 more

5 metrics

Number of grants 2 grants 2026 Cytokinetics Communications Grant Program

Program year Eighth annual Cytokinetics Communications Grant Program iteration

Video series length 5-part video series Living with HCM: Youth Voices from Camp Taylor

Campaign duration 6-month campaign Think. Know. Act.: Cardiomyopathy Awareness in Canada

Campaign scope 360° digital campaign Canadian SADS Foundation cardiomyopathy awareness effort

Market Reality Check

Price: $62.34 Vol: Volume 1,714,953 is 3% ab...

normal vol

$62.34 Last Close

Volume Volume 1,714,953 is 3% above 20-day average 1,673,006. normal

Technical Price $62.34 is trading above 200-day MA at $48.96 and 12.17% below 52-week high $70.98.

Peers on Argus

CYTK gained 3.49% while peers were mixed: AXSM +0.41%, LEGN +1.30%, ABVX +5.36%,...

CYTK gained 3.49% while peers were mixed: AXSM +0.41%, LEGN +1.30%, ABVX +5.36%, RYTM -2.59%, NUVL +1.35%, indicating a stock-specific move rather than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 27	HCM awareness campaign	Positive	+1.3%	Launch of 'On Track with HCM' whole-person impact awareness program.
Jan 27	Drug availability update	Positive	+1.3%	MYQORZO (aficamten) becomes available by prescription in the U.S.
Jan 20	Inducement equity grants	Negative	-1.2%	Inducement stock options and RSUs granted to new employees.
Jan 05	Conference presentation	Neutral	+5.5%	Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Dec 19	FDA drug approval	Positive	+4.6%	FDA approval of MYQORZO for symptomatic obstructive HCM in adults.

Pattern Detected

Recent CYTK news has generally seen positive price alignment, especially around MYQORZO-related milestones and corporate visibility events.

Recent Company History

Over the last few months, Cytokinetics has reported several milestones. FDA approval of MYQORZO on Dec 19, 2025 and later U.S. availability supported positive moves, as did an investor presentation at the J.P. Morgan conference. Awareness initiatives for hypertrophic cardiomyopathy, including the “On Track with HCM” program, also preceded modest gains. Today’s communications grants continue this theme of HCM community engagement, complementing prior regulatory and commercial progress rather than introducing new clinical or financial data.

Market Pulse Summary

This announcement highlights Cytokinetics’ continued investment in hypertrophic cardiomyopathy aware...

Analysis

This announcement highlights Cytokinetics’ continued investment in hypertrophic cardiomyopathy awareness through its eighth annual Communications Grant Program, funding 2 patient advocacy projects in 2026. These initiatives complement prior HCM-focused efforts and the MYQORZO approval on Dec 19, 2025, but do not introduce new clinical, regulatory, or financial information. Investors may watch how such outreach supports long-term engagement with the HCM community alongside commercial and regulatory developments.

Key Terms

hypertrophic cardiomyopathy, cardiomyopathy, arrhythmia, qr code

4 terms

hypertrophic cardiomyopathy medical

"organizations serving the hypertrophic cardiomyopathy (HCM) community"

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

cardiomyopathy medical

"Think. Know. Act.: Cardiomyopathy Awareness in Canada"

A condition that weakens or stiffens the heart muscle, reducing its ability to pump blood effectively; think of the heart as an engine that becomes less powerful or less flexible. For investors, cardiomyopathy matters because it can drive demand for medical treatments, affect healthcare costs, influence the value of companies developing drugs or devices, and trigger regulatory or insurance impacts that change revenues and risks across the healthcare sector.

arrhythmia medical

"The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation"

An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.

qr code technical

"including QR code cards that link families directly to a video library"

A QR code is a square, two‑dimensional barcode that stores information such as a website link, payment details, or product data and can be read instantly by a smartphone camera. For investors it matters because companies use QR codes to drive customer engagement, speed payments, track inventory, or provide instant access to reports and disclosures—similar to a digital shortcut that connects physical items or ads directly to online actions that can affect sales, costs, and transparency.

AI-generated analysis. Not financial advice.

Grants Awarded to Two Patient Advocacy Organizations 
to Support Communications and Community Outreach

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eighth annual Communications Grant Program, intended to support increased communications, awareness building and community engagement.

Two grants were awarded this year to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) community. The grants will support the organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing activities or outreach initiatives that would otherwise be challenging to implement.

“This year’s Cytokinetics Communications Grant Program recipients reflect the power of thoughtful, patient-centered communication in HCM,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement. “Through these grants, we are supporting important initiatives designed to expand awareness and education of HCM, amplify patient voices and strengthen community connections to help make a difference for patients and their families.”

The recipients of the 2026 Cytokinetics Communications Grants include:

Camp Taylor: Camp Taylor offers free, medically supervised programs for children with heart disease, including HCM. With support from the grant, Camp Taylor will produce Living with HCM: Youth Voices from Camp Taylor, a digital communications initiative designed to expand awareness and education around HCM. The project will include a five-part video series and a companion information toolkit for use in pediatric cardiology clinics. The video series will feature youth and families sharing their lived experiences with HCM in plain language, with bilingual subtitles to reach both English- and Spanish-speaking audiences. The clinic toolkit will provide printed and digital resources, including QR code cards that link families directly to a video library, helping healthcare providers connect newly diagnosed families with accurate, reassuring, and patient-centered information.

The Canadian Sudden Arrhythmia Death Syndrome (SADS) Foundation: The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation is a registered Canadian charity and the only patient advocacy organization in Canada dedicated to supporting individuals and families affected by inherited cardiac disorders. With support from the grant, the Foundation will develop Think. Know. Act.: Cardiomyopathy Awareness in Canada, a six-month, 360° digital communications campaign designed to support Canadian families affected by HCM and related conditions. The campaign aims to expand awareness of HCM symptoms, diagnosis, and management, while amplifying patient voices and fostering community engagement.

About the Cytokinetics Communications Grant Program

For the past eight years, the Cytokinetics Communications Grant Program has supported patient advocacy organizations to help expand their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Cytokinetics has no oversight, involvement or management of the actual projects, programs or outputs. The goal of the Communications Grant Program is to assist patient advocacy organizations by increasing resources in order to better support patient communities and bring increased disease awareness in the communities they serve. The call for proposals for the 2027 Communications Grant Program will be announced during Fall 2026.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the U.S. Food and Drug Administration and the China National Medical Products Administration. The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in first quarter in 2026. Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^TM is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

Who received Cytokinetics' Communications Grant Program awards on February 9, 2026 (CYTK)?

Two patient advocacy groups received the 2026 grants: Camp Taylor and the Canadian SADS Foundation. According to the company, grants support communications, awareness building and community outreach for families affected by hypertrophic cardiomyopathy (HCM).

What will Camp Taylor use the CYTK communications grant for in 2026?

Camp Taylor will produce a five-part digital video series and a clinic toolkit titled "Living with HCM: Youth Voices from Camp Taylor." According to the company, the materials include bilingual subtitles and QR-linked resources for pediatric cardiology clinics.

What is the Canadian SADS Foundation planning with Cytokinetics' 2026 grant (CYTK)?

The foundation will run "Think. Know. Act.: Cardiomyopathy Awareness in Canada," a six-month 360° digital campaign. According to the company, the campaign aims to expand awareness of HCM symptoms, diagnosis, management, and amplify patient voices in Canada.

How do Cytokinetics' 2026 communications grants aim to help newly diagnosed families (CYTK)?

Grants fund materials that connect families to patient-centered information quickly and accessibly. According to the company, projects include video libraries, QR-coded clinic toolkits, and bilingual content to reach English- and Spanish-speaking audiences.

Does Cytokinetics say the 2026 grants target specific outcomes for HCM awareness (CYTK)?

Yes. The grants are intended to expand awareness, education, and community engagement for HCM. According to the company, funded initiatives focus on amplifying patient voices, improving outreach, and providing accessible educational tools for families and providers.